MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

NovaVive Inc. Hires a Senior Vice-President, U.S. Sales & Marketing

NovaVive is pleased to welcome Robert (Bob) Barclay as Senior Vice-President, U.S. Sales & Marketing effective January 1, 2018. Bob has several years of experience in animal health, including 11 years with Zoetis Inc.

learn more

Iowa State University College of Veterinary Medicine to Conduct a Study with Immunocidin® Equine in Two Types of Cancer

NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.

learn more

Settle®, an Antibiotic Alternative for Treating Equine Endometritis, is Now Approved for Sale in New Zealand

NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.

learn more

Follow NovaVive on Social Media.